

16APR2020

V.1.8

## **Study Protocol - Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID)**

*A Randomised, Good-Practice-monitored, Placebo-controlled, double-blind study to clarify hospital length and risk of intensive care may reduce in hospitalized patients who have COVID-19 treated with azithromycin and hydroxychloroquine for 15 days after inclusion.*

Organisation: COP:TRIN – Chronic Obstructive Pulmonary Disease Trial Network:  
[www.coptrin.dk](http://www.coptrin.dk)

### **Hypothesis:**

→ In patients who are urgently admitted and who have a positive test for 2019-nCoV and symptoms similar to COVID-19 disease, treatment with corona virus inhibitor hydroxychloroquine as well as virus-immunomodulatory and antibacterial drug azithromycin can lead to shorter hospitalisation and fewer admissions in the intensive care unit.

This study is part of the Danish national non-commercial lung research network COP:TRIN ([www.coptrin.dk](http://www.coptrin.dk))

The study is conducted as a randomised controlled trial.

EUdraCT-no.: 2020-001198-55

ClinicalTrials.gov Identifier: NCT04322396

The Danish Medicines Agency case no.: 2020033414

The Danish National Committee on Health Research Ethics approval no.: H-20022574

The Danish Data Protection Agency journal no.: P-2020-258

Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalised Patients With COVID-19  
(ProPAC-COVID)

Principal investigator / Study director and scientific sponsor:

Research Associate Professor, Research Manager, Jens-Ulrik Stæhr Jensen, MD, PhD.

Research Unit, Pulmonary Medicine Section, Gentofte Hospital, Kildegårdsvej 28, 2900 Hellerup,

Tel: 38 67 30 57 + 28 93 81 68. Email: jens.ulrik.jensen@regionh.dk

Research Centres:

1. Pulmonary medicine section, Gentofte hospital, Kildegårdsvej 28, 2900 Hellerup

Primary investigator: Jens-Ulrik Stæhr Jensen.

Other investigators: Associate Professor, Senior Consultant Saher Shaker, Associate Professor,

Senior Consultant Torgny Wilcke, Senior Consultant Karin Armbruster, Post doc Pradeesh

Sivapalan MD, PhD, PhD student Josefin Eklöf, MD, Howraman Meteran, MD, PhD, Chief physician

Mette Vang Larsen, Chief physician Sidse Graff Jensen, PhD.

2. Pulmonary Medicine Department, Hvidovre Hospital, Kettegaard alle 30, Hvidovre

Primary Investigator: Professor Charlotte Suppli Ulrik

Other investigators: Chief physician Julie Janner, Mia Moberg, MD, PhD, PhD student Kjell

Håkansson, MD.

3. Pulmonary Medicine Section, Herlev Hospital, Herlev Ringvej, Herlev

Primary Investigator: Professor Peter Lange

Other investigators: Hans Henrik Lawaetz-Schultz, MD, PhD, Chief physician Vibeke Gottlieb, Chief physician, Christian Søborg, PhD, Chief Physician Pernille Ravn, PhD.

4. Pulmonary and infectious medicine department, North Zealand Hospital, Dyrehavevej 29, 3400 Hillerød

Primary Investigator: Chief physician Andrea Browatzki

Other investigators: Chief physician Birgitte Lindegaard Madsen, DMSc, Chief physician Zitta

Barrella Harboe, PhD, Senior Consultant Thyge Lynghøj Nielsen, PhD.

5. Pulmonary Medicine Department, Aalborg Hospital, Hobrovej 18 -22, 9000 Aalborg

Primary investigator: Associate Professor, consultant, PhD, Ulla Møller Weinreich

Other investigators: PhD student Peter Ascanius Jakobsen, PhD student Mia Solholt Godthaab Brath.

6. Pulmonary Medicine Section, Medical Department, Roskilde Hospital, Roskilde

Primary investigator: Chief physician, PhD, Christian Niels Meyer

Investigator: post doc, Principal Education Doctor, Pradeesh Sivapalan

7. Pulmonary Medicine Department, Bispebjerg Hospital, Bispebjerg Bakke 23, 2400 Copenhagen

Primary investigator: Research Associate Professor, Chief Physician, PhD, Therese Lapperre

## Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID)

### 8. Medical Department, Slagelse Hospital

Primary investigator: Research Associate Professor, Doctor, PhD. Uffe Bødtger.

9. Medical department, Odense University Hospital Primary investigator: Research Associate Professor, Chief Physician, PhD. Christian B. Laursen Investigator: Professor, Chief Physician, DMSc, Isik Somuncu Johansen

### Other participants (not experimental centres)

1. Infectious Medicine Department, Rigshospitalet, Blegdamsvej, Copenhagen Ø.

Primary Investigator: Professor Jens D. Lundgren

2. Intensive Treatment Section 41.31, Rigshospitalet, Blegdamsvej, Copenhagen Ø. Professor, Chief Physician, Anders Perner, DMSc

3. Center for Rheumatology and Spine diseases, Rigshospitalet, Blegdamsvej, Copenhagen Ø. Professor, Chief Physician, Søren Jacobsen, DMSc

4. Intensive care unit, Gentofte Hospital, Niels Andersen road 65, 2900 Hellerup.  
Head of Section, Thomas Mohr, Ph.D.

5. Intensive therapy section, NOH, Hillerød, Helsevej 2, 3400 Hillerød Research Associate Professor, Morten Bestle, Ph.D.

6. Cardiology department, Herlev-Gentofte Hospital, Niels Andersens Vej 65, 2900 Hellerup  
Associate Professor Tor Biering-Sørensen Ph.D.

7. Clinical pharmacology department, Bispebjerg Hospital, Bispebjerg Bakke 23, 2400 Copenhagen  
Associate Professor, Doctor, Ph.D. Tonny Studsgaard Petersen

8. Cardiac Catheterization Laboratory 20.14, Heart Center, Rigshospitalet, Blegdamsvej, Copenhagen Ø  
Professor, Jens Kastrup, DMSc

### GCP monitoring:

The GCP units by GCP coordinator Kristina Devantier

COP:TRIN, Steering Committee: Please see: <http://coptrin.dk/steering-committee-members/>

### Background information on the medicine used in this trial:

#### Pill Azithromycin

Categorized as an antibacterial agent. The drug is an approved and marketed drug in Denmark for use in upper and lower respiratory tract infections and is also used according to the evidence in the field and the current guidelines for the treatment of severe asthma, COPD and bronchial

## Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID)

infections (for all of these due to lack of disease control and frequent exacerbations). Please see enclosed product summaries for further information.

Pill Hydroxychloroquine:

Categorized as an anti-inflammatory and anti-malaria agent.

The drug is approved and marketed in Denmark for the prevention and treatment of malaria, for the treatment of rheumatoid arthritis, discoid and systemic lupus erythematosus and juvenile idiopathic arthritis.

Manufacture, packaging, labelling, etc.:

The trial drugs are manufactured by Glostrup pharmacy by pharmacist Kristian Østergaard Nielsen. Placebo capsules are thus made similar to the intervention medicine. The drugs (and Placebo) are labelled according to Appendix 13. Glostrup pharmacy has a key for blinding. Therefore, it will always be possible to blind a patient if indicated. Investigator must notify sponsor on grounds if a patient is blinded.

Medical professionals dispense the medication/placebo during hospitalization daily, except for patients who prefer self-medication. In the latter case, a medicine diary is made (handed out at present). For all patients who are discharged during the intervention period, a medication diary is made. The medication diary is subsequently collected.

Exactly the amount of medication or placebo that the patient needs to take, is given to them, but for patients who do not take all the medication (protocol deviation), the remaining medication will have to be handed over to study staff (patient instructed). The patient will receive a follow-up phone call to check whether they have taken the medication in accordance with the trial protocol.

### **1. Hypothesis and aims:**

#### 1.1 Hypothesis:

In patients with acute hospitalisation who have a positive test for 2019-nCoV and symptoms similar to COVID-19 disease, treatment with virus-modifying agent hydroxychloroquine as well as virus-immunomodulatory and antibacterial drug azithromycin can lead to shorter hospitalisation and fewer admissions to the intensive care unit.

#### 1.2 Aims:

The aim of this randomised GCP-controlled trial is to clarify whether combination therapy with macrolide azithromycin and hydroxychloroquine via anti-inflammation/immune modulation, antiviral efficacy and pre-emptive treatment of supra-infections can shorten hospitalisation

# Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID)

duration (measured as "days alive and out of hospital", Primarily outcome), reduce the risk of non-invasive ventilation, intensive care and death.

## 2. Background and scientific perspective:

### 2.1 Background - rationale

#### *Coronavirus - COVID-19*

In the ongoing coronavirus pandemic, COVID-19, occurring in Wuhan, China, there is still sparse data on the course, risk of various complications, and how patients who are hospitalised are best treated to ensure high survival and short hospitalisation. The most frequent symptoms are fever (> 80%) and cough (70-80%), and radiologically most commonly found "frosted-glass" or "patchy infiltrates" in the sickest patients (86%), which are compatible with severe viral pneumonitis (1, 2). The length of hospitalisation is observed to be relatively long, 10-15 days (3), which in itself is a problem as hospitals can quickly reach the maximum capacity for hospitalisation and the proportion of patients who become critically ill have, on the observations reported so far, had a mortality rate of > 60% (4), and overall mortality for admitted patients in China with COVID-19 infection is apparently unusually high for viral respiratory tract infections. ca. 25% (2).

#### *COVID-19 and lung disease*

Only specific data on patients with Chronic Obstructive Pulmonary Disease (COPD) have been reported in a few studies, but the risk of death is apparently extremely high (OR 5.4 [95% CI 0.96-30.40]) (2).

#### *Lack of specific treatment*

Despite the rapid spread of the disease globally, there is no solid data yet to recommend any specific treatments, which is why symptomatic, organ supportive therapy is recommended. respiratory therapy in acute pulmonary failure (5). A high incidence of bacterial super-infections has been reported in patients with COVID-19 who died (50%) vs. in survivors (1%),  $p < 0.0001$ , just as those who died had an incidence of septic shock of 70% vs. 0% (2). Thus, there is an urgent need for treatments that can improve the patient's chance of receiving as short-term hospitalization as possible, and with the lowest risk of secondary infections, hospitalisation and death.

#### *Macrolide azithromycin as a possible treatment for patients with COVID-19*

Azithromycin is a macrolide antibiotic that has shown convincing efficacy in several studies in recent years to reduce hospitalisation-related exacerbations in COPD (6, 7), asthma (8), and to prevent acute exacerbations in patients with bronchiectasis (9). At the same time, it is observed that azithromycin has a distinct effect by modulating airway inflammation in the direction of anti-

## Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID)

inflammation by reducing CXCL1, TNF-alpha, IL-13 and IL-12p40 (10) and further, a strong association between survival by Acute Respiratory Distress Syndrome (ARDS) and administration of azithromycin (HR for 90 days of death for all causes: 0.49 [95% CI 0.27 - 0.87] in a well-conducted study of critically ill patients (11).

Furthermore, it has been consistently observed in several recent publications that azithromycin itself appears to have an antiviral effect on several viruses causing respiratory tract infections, such as Respiratory Syncytial Virus (RSV) (12), Rhinovirus (13) and furthermore for Zika virus (14).

### *Hydroxychloroquine as immunomodulatory and antiviral agent by COVID-19*

Hydroxychloroquine is a drug that has been known since 1934 and is used as an anti-inflammatory agent for rheumatoid arthritis, as the prevention and treatment of malaria, but in addition to these effects, it is well described that the drug has an antiviral effect especially against flavivirus, retrovirus and coronavirus by inhibiting a number of low-pH-dependent steps in virus replication, as well as by inhibiting the pH-dependent endosomal mediated viral uptake in cells (15). The drug is extremely well tolerated in high doses, for up to 5 years and there is no signal for birth defects with usage of the drug summarised by Savarino et al. (15). Large daily doses of hydroxychloroquine are given over many years to patients with arthritis such as systemic lupus erythematosus and rheumatoid arthritis for anti-inflammatory purposes, which is generally well-tolerated (16).

Cell studies with primate cells with the coronavirus that induced SARS-1 (formerly called SARS) have shown that chloroquine, in a dose-dependent manner, inhibits the ability of the corona virus to infect cells and to spread among cells (17). Thus, several researchers and therapists in connection with the current Corona pandemic have proposed studies examining hydroxychloroquine/chloroquine as treatment for patients with COVID-19 disease (18, 19).

### 2.2 Scientific perspective for this study

The study will clarify whether drug treatment with azithromycin in combination with hydroxychloroquine for 15 days from hospitalisation with diagnosed COVID-19 infection in hospitalised patients may reduce the length of hospitalisation, the risk of hospitalisation in the intensive care unit, treatment with non-invasive ventilation and death. The study will also clarify whether this treatment can reduce the need for oxygen supplementation (time for breathing on its own without oxygen supplementation) or for regular Long-Term Oxygen Therapy oxygen supplementation ("home oxygen").

If the treatment works to improve the course of COVID-19 infection also in lung patients, a very large number of patients could benefit from the treatment immediately.

The study is of the Danish national non-commercial lung research network COP:TRIN (Chronic Obstructive Pulmonary Disease: Trial Network).

# Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID)

## 3. Method:

### 3.1 Design:

Randomized, Good-Practice-monitored, Placebo-controlled, double-blind study.

### 3.2. Recruitment and inclusion:

See point 12.

### 3.3 Inclusion:

#### Inclusion criteria:

- Patient admitted to a Danish emergency department, respiratory medicine department or internal medicine department
- Age > 18 years
- Hospitalized <48 hours
- Positive COVID-19 test / diagnosis during the hospitalization (confirmed).
- Fertile women\* must not be pregnant, i.e. negative pregnancy test must be available at inclusion
- Informed consent signed

\* Defined as after menarche and until postmenopausal (no menstruation for 12 months)

#### Exclusion criteria:

- At the time of recruitment, the patient uses  $\leq 5$  LO<sub>2</sub>/min (equivalent to 40% FiO<sub>2</sub> if measured)
  - o Note: 5 LO<sub>2</sub>/min is allowed, it is only >5 LO<sub>2</sub>/min that it is the basis for exclusion.
- Known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to quinine or 4-aminoquinoline derivatives
- Neurogenic hearing loss
- Psoriasis
- Retinopathy
- Maculopathy
- Visual field changes
- Breastfeeding
- Severe liver diseases other than amoebiasis (INR > 1.5 spontaneously)

## Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID)

- Severe gastrointestinal, neurological and hematological disorders (investigator-assessed)
- eGFR <45 ml/min/1.73 m<sup>2</sup>
- Clinically significant cardiac conduction disorders/arrhythmias or prolonged QTc interval (QTc (f) of > 480/470 ms).
- Myasthenia gravis
- In treatment with digoxin\*
- Glucose-6-phosphate dehydrogenase deficiency
- Porphyria
- Hypoglycaemia (Blood glucose at any time since hospitalization of <3.0 mmol/L)
- Severe mental illness which significantly impedes cooperation
- Severe linguistic problems that significantly hinder cooperation
- Treatment with ergot alkaloids

\*The patient must not be treated with digoxin for the duration of the intervention. For atrial fibrillation/flutter, select according to the Cardiovascular National Treatment Guide (NBV): Calcium antagonist, Beta blocker, DC conversion or amiodarone. In case of urgent need for digoxin treatment (contraindication for the aforementioned equal alternatives), the test drug should be paused, and ECG should be taken daily.

### Drug Interactions

Interactions should be taken into account if the patient is taking other medications. The interactions are described in the respective product summary of the drugs. For azithromycin, this includes antacids, ergotamine derivatives, colchicine and cyclosporine. For hydroxychloroquine, these include antidiabetic agents, tricyclic antidepressants, antipsychotics halofantrine, cyclosporine, mefloquine, antiepileptic drugs, praziquantel and agalsidase.

### Standard Treatment

As there is no specific treatment for COVID-19, standard assessment and treatment is based on organ supportive therapy such as oxygen therapy (central), fluid therapy, antibiotic therapy for secondary infections. If the oxygen treatment that can be given in the normal trunk section is not enough to oxygenate the patient satisfactorily, lung-supportive treatment will often be respiratory therapy on an intensive therapy section.

In addition, reference is made to the national instructions regarding details of this - it can be found at [www.lungemedicin.dk](http://www.lungemedicin.dk). The document can be attached if needed. It is on 21 pages and is therefore omitted from the Protocol for reasons of space.

## Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID)

### 3.3.2. Allocation:

The sponsor generates a randomisation sequence. Randomisation will be in blocks of unknown size and the final allocation will be via an encrypted website (REDCap), where also inclusion and exclusion criteria are required to be filled out correctly to randomise a patient.

There will be stratified for age (>70 years vs. ≤70 years), site of recruitment and whether the patient has any of the following chronic lung diseases: COPD, Asthma, Bronchiectasis, Interstitial lung disease (Yes vs. No).

### 3.3.3. Data collection, surveys and follow-up:

The primary daily project management is carried out by the project manager. In addition, a project group (investigators), consisting of doctors from the departments involved, is trained to assist the project manager with the recruitment, sampling and follow-up of patients. All medical decisions regarding patients will be taken by a physician. Data is collected on Case Report Forms (CRF), specific to each patient.

Prior to consent to participate in the trial, we will only assess the specific information needed to assess inclusion and exclusion criteria. No other information will be assessed.

It is the attending physician who asks if patients are interested in hearing more about the trial. If yes, contact the investigator and inform the patient.

As part of the study, all patients will be monitored for oxygen saturation, heart rate, blood pressure, respiratory rate and temperature during hospitalisation.

Furthermore, these are also registered:

- Date of birth, age and gender
- Height, weight and BMI
- Trial medicine
- For patients with chronic obstructive pulmonary disease (COPD) classification in GOLD 1-4 and GOLD A-D and MRC degree
- Systematic screening for co-morbidities
- Smoking history with pack years, current smoking status and alcohol consumption
- Information from the chest x-ray
- Arterial-gas analysis (pH, pCO<sub>2</sub>, pO<sub>2</sub>, Base Excess, oxygen supplementation)
- Hb, leucocytes + differential count, CRP, renal parameters, liver parameters, electrolyte parameters, LDH
- ECG, vital status, and adverse events

From the patient journal the following is obtained:

- CT thorax
- Home oxygen supplementation and dosage

## Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID)

- Home NIV, acute NIV and respirator therapy
- Re-admission
- Current use of medicine

All this information is passed on to the researcher. The journal information is needed to calculate demographic data, medication data and outcomes in the trial. No information that is unnecessary to the protocol will be obtained.

Case Report Form is archived at the departments involved for 15 years. A separate database is created in REDCap ([www.projectredcap.org](http://www.projectredcap.org)) for data management.

**Table 1: An overview of examinations that each participant will undergo:**

	Inclusion/Day 1	Day 2-3	Day 4	Day 5 to discharge
Informed consent	X	-	-	-
Blood sample*	X	X	X	X
Pregnancy test (only fertile women)	X			
Arterial gas test	X	-	X	-
ECG**	X	X***	X	X
Weight measurement	X	-	-	-
Height measurement	X	-	-	-
MRC score + GOLD****	X	-	-	-
Oxygen supplementation (L/min) (open)	X	X	X	X
FiO2 (%) (respirator)	N/A	X	X	X
Chest x-ray	During hospital admission			

\*The blood samples include haemoglobin (Hb), leukocytes + differential count, C-reactive protein (CRP), Na+, K+, albumin, creatinine, urea, amylase, alkaline phosphatase, beta-2-Microglobulin, fibrinogen, glucose, TSH, INR, bilirubin, D-dimer, APTT, calcium, triglycerides, ferritin and lactate

## Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID)

dehydrogenase (LDH). These blood tests will also be recommended daily for COVID patients outside studies in the recommendation of the Danish lung medicine association. ECG\*\*: When screening for the study, an ECG can be used from the current hospitalisation, or other ECG from the last 3 days. A follow-up ECG, in addition to that taken on day 1, is taken during the remaining days of the trial. \*\*\*Reg. ECG. \*\*\*\*Only in patients with COPD.

### 3.3.4 Intervention

Everything below is blinded and with placebo to the control group. Neither patients nor study staff will know which group the patient is allocated to. The medicine will be marked neutral, e.g. "Azithromycin group A" and "Azithromycin group B" and also for Hydroxychloroquine.

NOTE: If the patient is receiving azithromycin prophylaxis, common practice is followed by emergency hospitalisation: the prophylaxis is paused and then restarted as usual.

#### Control group:

The control group will receive the standard treatment + placebo for both types of intervention medication at all times. If part or all the intervention therapy being investigated becomes standard treatment during the study, this may also be offered to the control group.

#### Intervention group:

The patients in the intervention group will also receive standard care. Immediately after randomisation to the intervention group, the patient is put into further treatment with:

#### Azithromycin:

Day 1-3: 500 mg x 1

Day 4-15: 250 mg x 1

If the patient is unable to take the medication p.o. self, is attempted with either stomach-probe administration, or alternatively, temporary transition to clarithromycin 500 mg x 2 (this only in agreement with either study coordinator Pradeesh Sivapalan or principal investigator Jens-Ulrik Stæhr Jensen). The patient will switch back to azithromycin when possible.

#### Hydroxychloroquine:

Furthermore, the patient is treated with hydroxychloroquine in the dosage:

Day 1-15: 200 mg x 2

Follow-up is done on days 14, 29, 90 and 365 days. This is done through the journal system. The specific information obtained, and its purpose can be found in section 3.3.3.

## Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID)

Regarding dosage

The Summary of Product Characteristics for Azithromycin suggests 500mg/day for three days or 500mg/day for one day and then 250mg daily for four days. However, other clinical studies have found a positive effect of a daily dose of 250 mg for prolonged periods as prophylactic treatment. Mortality among hospitalised patients with COVID-19 is quite high and the median time to hospitalisation is 10-15 days, so it seems reasonable to give patients prophylactic dose for 12 days.

The dosing of hydroxychloroquine follows the summary of product characteristics.

Regarding other treatment with antibiotics:

If antibiotic therapy is deemed indicated to the patient due to e.g. If pneumonia is suspected or if it is introduced as standard therapy, or by other suspicion or confirmation of a secondary bacterial infection, piperacillin-tazobactam should be given as an empirical treatment at a dose appropriate to renal function, weight and age. In case of penicillin allergy, cefuroxime is also given at a dose appropriate to renal function, weight and age. When microbiology is available, immediately switch to targeted treatment.

If *specific suspicion of atypical pneumonia* is suspected, ciprofloxacin is administered at a dose of corresponding to kidney function and concomitant examination for atypical pneumonia. If negative, ciprofloxacin is discontinued. If positive, ciprofloxacin treatment is continued for the duration of treatment corresponding to the microorganism detected. If there is a specific need for treatment with macrolide and where other options are not available (e.g. allergy to fluoroquinolones, or when there is an estimated need for combination treatment of e.g. legionella pneumonia), consult with an investigator, and in this case it may be decided to discontinue azithromycin (active) or azithromycin placebo. In this case, treatment stops without blinding.

Furthermore, ECG is recorded at inclusion (ECG from current hospitalisation and any other ECG within 3 days can be used), as well as a follow-up ECG during the other days of the trial: Focus on QTc. At QTc (F) > 480/470 ms for respectively women and men, refrain from further study medicine (but the patient remains in the study).

3.3.5. Statistical analyses:

Primary endpoint:

- Number of days alive and discharged from hospital within 14 days (summarises both whether the patient is alive and discharged from hospital) ("Days alive and out of hospital")

Secondary endpoints:

Secondary endpoint no. 1:

Ordinary outcome. The patient is categorized into one of the following 8 categories on day 15:

## Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID)

1. Dead
2. Hospitalised and mechanical ventilation or ExtraCorporalMembraneOxygenation (ECMO)
3. Hospitalised and Non-invasive ventilation or high-flow oxygen device
4. Hospitalised and given oxygen supplements that do not live up to oxygen supplements in (2) or (3) - e.g. oxygen on "nostrils"
5. Hospitalised and do not receive oxygen supplementation but need treatment (COVID-19 related or other)
6. Hospitalised and do not receive oxygen supplements and do not need treatment (just observed)
7. Discharged with restriction on activities, may be free of oxygen depletion or use LTOT ("home oxygen")
8. Discharged, no restrictions on activities

### Other secondary endpoints:

- Admitted to the intensive care unit in the two groups (0 vs. 1) during the index admission
  - o For patients admitted to intensive care unit: number of days on intensive care (Length of stay, ICU)
- Have used Non-invasive ventilation, NIV (0 vs. 1) during index hospitalisation
- Died on day 30
- Days spent in hospital during index admission
- Days alive and discharged from hospital within 30 days (summarises both whether the patient is alive and discharged from hospital)
- Death on day 90 (reported later)
- Died within 12 months (reported later)
- Number of readmissions for all causes within 30 days
- Number of days of non-invasive ventilation (NIV) or respiratory therapy during index admission
- Delta PaO<sub>2</sub> day 1 (baseline) to day 4 (72 hours). At the same time oxygen supplements and oxygen systems are registered
- Delta PaCO<sub>2</sub> day 1 (baseline) to day 4 (72 hours)
- pH day 4 (72 hours)
- Time to no oxygen supplement (or regular LTOT oxygen supplement)

In addition, several explorative endpoints - See additional protocols.

## Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID)

Data is processed and analysed in SAS v.9.4 and graphs are generated in Microsoft Excel and SigmaPlot.

### 3.3.6. Sample size:

#### Randomised controlled study

Prerequisite: Type 1 error rate = 5%. Power = 80%. 2-sided statistics. Group sequential design with 1 scheduled interim analysis in 113 patients (½ recruitment).

Analysis: T-test.

Sample size is calculated based on the following estimate and indicative figures:

Expected hospitalisation with COVID-19: 10 days

SD for "Days alive and discharged within 14 days" in patients with lung disease and COVID-19: 4 days (up to 10 days hospitalization)

Employee detection for improvement/deterioration: 1.5 days.

This requires 226 patients randomized 1:1 with 113 in each group. This is a fixed sample size. It is assumed that most patients complete the intervention.

However, for interim analysis, the Data and Safety Monitoring Board (DSMB) may recommend the steering committee to expand sample size.

### 3.3.7 GCP Monitoring:

Frequency and depth are determined by the GCP units. Initiation visits and the first monitoring visits to all centres will be conducted off-site, i.e. without a physical meeting, due to the lack of opportunity due to the Corona pandemic. Consent sheets will be scanned into an online system (REDCap or journal system) that can be accessed by GCP monitors.

## **4. Interim Analysis and Data and Safety Monitoring Board**

After recruiting half the sample size (approximately 113 patients), an interim analysis is done focusing on safety. An external Data and Safety Monitoring Board is appointed.

The interim analysis will be prepared and presented by physician Josefin Eklöf. The groups will be presented as "Group A" and "Group B" and DSMB will only be blinded if they ask the steering committee for the study on this and if the steering committee agrees.

## **5. Blood samples:**

As part of regular treatment, blood samples are taken daily from the time of inclusion and as long as the patient is admitted. Blood samples include haemoglobin (Hb), leukocytes + differential count, C-reactive protein (CRP), Na<sup>+</sup>, K<sup>+</sup>, albumin, creatinine, urea, amylase, alkaline phosphatase, beta-2-Microglobulin, fibrinogen, glucose, TSH, D-dimer, APTT, calcium, triglycerides, ferritin, bilirubin, ALAT, INR, and lactate dehydrogenase (LDH), see Table 1. These blood samples are analysed at department of clinical biochemistry at the hospitals.

In addition, supplemental blood tests and material obtained with nasal swabs will be performed according to supplemental protocols. Material from this will be included in the research biobank, and after completion of the experiment in the biobank (for details see supplementary protocol). The trial is expected to end in February 2021, and the material will then be transferred to the biobank.

For the project, the results of blood tests are collected from the patient record.

## **6. Side effects, risks and disadvantages:**

The treating physician may at any time discontinue intervention with azithromycin and/or hydroxychloroquine if, in clinical and/or paraclinical assessment, it is deemed contraindicated.

### Blood tests:

Serious side effects to regular blood sampling (venous puncture) are rare. Frequent (5-15%) can be seen transient discoloration of skin around the insertion site due to less skin, subcutaneous and spatias (natural cavities).

### X-ray:

X-rays of the lungs are exposed to a radiation dose of approx. 0.1 millisievert (mSv). This should be compared with the average background radiation in Denmark of approx. 3 mSv per year. There are no documented adverse effects of the radiation dose received by X-rays in the literature. Therefore, we believe that the study is not associated with any risks or side effects.

### Side effects of the trial medicine:

See [www.medicin.dk](http://www.medicin.dk)

### Azithromycin:

Very common (>10%) Abdominal pain, Diarrhoea, Flatulence, Nausea.

## Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID)

Common (1-10%) Powerlessness, Decreased appetite. Vomiting, Taste Disorders. Decreased lymphocyte count. Decreased serum bicarbonate. Arthralgia. Headaches, Paraesthesia, Dizziness. Skin itching, rash. Visual disturbances.

Uncommon (0.1-1%) Pain. Hepatitis, Oral candidiasis. Dyspnea, Pneumonia, Oedema. Eosinophilia, Leukopenia, Neutropenia. Elevated serum bicarbonate, Hyperchloremia, Hyperglycaemia, Hyperkalaemia, Hyponatremia, Hypokalaemia, Hyponatraemia. Arthritis, Back Pain. Nervousness, Somnolence. Facial oedema, Dermatitis, Photosensitivity. Candidiasis, Infections. Metrorrhagia, Kidney Pain, Testicular Disease, Vaginitis. Hearing loss, Tinnitus.

Rare (0.01-0.1%) Cholestasis, Liver Impact. Agitation. Acute generalized exanthematous pustulosis\*, Allergic reactions\*, Angioedema\*, Hypersensitivity.

Not known Fulminant hepatitis, Hepatotoxicity, Hepatic insufficiency, Pancreatitis, Pseudomembranous colitis. Arrhythmias, Extended QT interval, Hypotension, Torsades de pointes tachycardia. Haemolytic anaemia, Thrombocytopenia. Aggravated myasthenia gravis. Aggressiveness, Anxiety, Delirium, Hallucinations, Hyperactivity, Hypesthesia, Seizures, Syncope. DRESS - drug reaction with eosinophilia and systemic symptoms, Erythema multiforme, Stevens-Johnson syndrome, Toxic epidermal necrolysis. Anaphylactic reaction. Acute renal failure, Interstitial nephritis.

\* In case of allergic reactions, including acute generalized exanthematous pustulosis and DRESS, azithromycin should be discontinued.

### Hydroxychloroquine:

Very common (> 10%) Abdominal pain, Nausea.

Common (1-10%) Eating refusals. Diarrhoea, Vomiting. Emotional lability, Headaches. Skin itching, rash. Accommodation difficulty.

Uncommon (0.1-1%) Liver effect. Nervousness, Sensomotor disorders, Dizziness. Alopecia. Corneal oedema, Double vision, Retinopathy \*, Tinnitus.

Not known Fulminant liver failure. Bronchospasm, Extended QT interval\*\*, Cardiomyopathy. Aplastic Anaemia, Bone Marrow Depression, Influence of the Blood Image (agranulocytosis, anaemia, leukocytopenia, thrombocytopenia). Aggravation of Porphyria, Hypoglycaemia. Myopathy. Extrapyramidal genes, Cramps, Neuropathy, Palsy, Psychosis, Suicidal behaviour. Acute generalized exanthematous pustulosis\*\*\*, Exfoliative dermatitis, Erythema multiforme, Photosensitivity, Stevens-Johnson syndrome, Toxic epidermal necrolysis. Allergic reactions (including DRESS syndrome), Angioedema. Hearing loss, Macular and retinal degeneration, Maculopathy.

\* Retinopathy with:

## Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID)

- Retinopathy with pigment change requires careful dosing and careful control. When using rheumatologic doses, eye examination by an ophthalmologist is recommended before starting treatment. Then check for any eye manifestations that may arise. Annual monitoring after 5 years of treatment is recommended, however in risk patients initially annual control, see also Chloroquine derivatives (inflammatory rheumatic diseases), side effects.
- Cardiomyopathy can be fatal.
- Macular degeneration is seen and may be irreversible.
- Reversible corneal changes with oedema and blemishes can cause blurred vision or photophobia.
- Blurred vision accommodation is dose-dependent and reversible.
- In malaria treatment and prophylaxis, fewer and milder side effects occur.

\*\* Prolonged QT interval has been seen in patients with particular risk factors.

\*\*\* Acute generalized exanthematous pustulosis must be distinguished from psoriasis. Psoriasis exacerbation may occur. May be associated with fever and hyperleukocytosis.

An adverse reaction (AR) is defined as any adverse and undesirable reaction to a trial drug regardless of dose. An adverse event (AE) is defined as any adverse event in a patient or subject in a clinical trial following treatment with a drug, without necessarily linking this treatment to the adverse event.

Since the trial drugs are well known and have been used for many years, we will only record side effects not mentioned in the respective drug summary of the trial drug.

A severe adverse reaction or event (SAR/SAE) is defined as an event or adverse event that, regardless of dose, results in death, is life-threatening, results in hospitalization or prolongs hospitalization, results in significant or persistent disability or incapacity, or leading to a congenital anomaly or malformation.

Investigators must immediately (= within 24 hours) report serious incidents and serious adverse reactions (SAEs and SARs) to the sponsor regardless of whether they are described in the respective product summary. This allows the sponsor to assess the benefits and risks along the way in the study.

Events and adverse events recorded during the period from the patient have received the first dose of trial medication up to and including day 15.

Recording and reporting of all events and adverse events will end when the trial drug is stopped.

A high degree of comorbidity and death is seen in this patient group and therefore it is also expected that prolonged admissions, re-admissions, NIV, Respirator treatment and death will occur in this patient group. Therefore, these parameters will not be considered an SAE.

## Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID)

All incidents and registered side effects are reported at the end of the trial medicine in a final report to the Danish Medicines Agency. All serious suspected adverse reactions must be reported annually together with a report on the safety of the subjects and sent to respectively the Danish Medicines Agency (LMST) and the Danish National Committee on Health Research Ethics (VEK).

The product summary of the trial drugs is used to assess whether a serious adverse event is unexpected and thus possibly a Suspected Unexpected Serious Adverse Reactions (SUSAR).

In the event of a fatal or life-threatening SUSAR, this must be registered and reported to LMST and VEK within 7 days of the sponsor becoming aware of it. No later than 8 days after the report, the sponsor must provide LMST and VEK with all relevant information about the sponsors and investigators' follow-up on the report. All other SUSARs are reported to LMST and VEK within 15 days of the sponsor becoming aware of them.

The report must be followed up by a detailed written report, and in both the immediate report and the subsequent report, the investigator must identify the subjects with a personal code number. When reporting deaths, the investigator must provide any additional information that the sponsor may request.

### **7. Economy:**

The research project is (investigator) initiated by COP:TRIN. Fund support has been obtained from the Novo Nordisk Foundation of DKK 2.2 million for sponsor, remuneration of auxiliary personnel, payment of laboratory tests and equipment, as well as for hydroxychloroquine and azithromycin treatment. The sponsors and investigators are not financially linked to private companies, foundations, etc. in this research project.

Budget:

See budget in separate Excel file.

Medical expenses are covered, if not obtained from other sources, by the section for respiratory medicine research, Gentofte Hospital.

To the extent possible, the section for respiratory medicine research, Gentofte Hospital supports follow-up for endpoints and otherwise by appointment.

### **8. Remuneration:**

Patients are not paid for participation.

### **9. Availability of information and right to data:**

The consent gives the probation officer, monitor and any control authority direct access to obtain information in the patient's record, etc., including electronic record, in order to see information about the subject's health conditions which are necessary as part of the implementation of the research project and for control purposes, including self-monitoring, quality -control and monitoring which they are required to perform.

The project group that has designed and conducted this study has the right to data and the right (and duty) to publish based on data. Project management manages data and invites members of the project to publications. All sites that recruit patients are entitled to at least one spot on the primary publication, and for every 10 patients recruited, the site is entitled to an extra authorship. Sites that have not participated in the design of the study are entitled to a maximum of 3 authorships. It is the opinion of the steering committee that knowledge sharing creates more and better scientific results. Requests for knowledge sharing from other groups will be submitted to Project Management (Jens-Ulrik Jensen, Charlotte Ulrik, Pradeesh Sivapalan) who will evaluate primarily and who, if the project is found suitable, will discuss it with the COPTRIN Steering Committee.

Project Management has the first right to undertake sub studies but may well assign projects to other contributors. In that case, the following considerations will be significant in the assessment: 1) Participation in the design phase of this RCT and at what level; 2) number of patients recruited at a site. If the hypothesis to be investigated is not planned to be examined by our group, we will allow the use of our data if the Steering Committee finds the project scientifically sound and, if appropriate, a collaboration with members of the COPTRIN Steering Committee will be proposed. However, it should be emphasized that data is used for a specific purpose, not for future purposes in general. This becomes conditional by the steering committee for data to be used in a sound way to test hypotheses with relevant scientific content.

Information regarding subjects are processed and stored in accordance with the **Data Protection Regulation (GDPR)**, the Data Protection Act and the Health Act and the project is properly notified in accordance with applicable rules and laws to the appropriate authorities.

### **10. Publication of results:**

All project results will be published in scientific contexts, including international journals. This will happen regardless of whether the result is positive, negative or inconclusive.

## **11. Scientific Ethics Statement:**

The study is conducted in accordance with the Declaration of Helsinki and is carried out in accordance with the rules of the Personal Data Act and the Health Act. The study is reported to the Danish Data Protection Agency.

Recruitment and inclusion will take place as previously described (section 3.3.1). Participation requires a signed statement of consent. Patients can withdraw their participation consent and withdraw from the research project at any time without affecting their right to current or future treatment. Furthermore, the patient is entitled to bring a bystander to the information interview and is entitled to reflection time before any declaration of consent is signed.

The important objective of the study is to investigate whether pro-active and *pre-emptive* treatment against COVID-19 can reduce the length of hospitalisation and the risk of intensive care and improve the survival of patients - an area that has so far been scantily illuminated and where the need for evidence-based guidelines for handling and processing is large and very urgent.

Potential disadvantages and side effects are described in the separate section 5. Among other things, it appears that the likelihood of serious adverse reactions to both treatment and studies is rare. In addition, the treating physician can always discontinue treatment if it is considered contraindicated.

Placebo is given in the control group as no specific standard medical treatment is available.

The experimental method and statistical analyses have been carefully considered in order to be able to disseminate and apply relevant and secure research results to clinical practice.

Based on the above considerations, we believe that the experiment is sound ethically sound and can be conducted without exposing the test participant to unjustifiable risks.

## **12. Recruitment of subjects and informed consent**

At each trial centre, screening of patients admitted with a positive COVID-19 test is performed. Patients are assessed against the inclusion and exclusion criteria of the attending physician who receives the patient's consent to contact the investigator. The Investigator then contacts the patient for recruitment to the study. Disclosure of information about the study and obtaining informed consent may also be undertaken by other healthcare professionals. This includes research assistants (medical students) clinical nursing specialists and project nurses (See below for specific requirements). These are all separately trained in the task and have the opportunity to call a physician should any medical issues arise. They can also contact the coordinating investigator as well as a hotline team for the trial should any questions arise about informed consent. This hotline is available 24 hours a day. All patients are offered a consultation with a physician and get this if they wish. For project nurses, the following applies specifically: i) must have at least 5 years of

## Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID)

seniority; These requirements are verified by primary investigator from each site creates a document for these individuals from which the above specific requirements are verified. This document is dated and signed.

The possibility that other people than doctors can inform patients about the trial is limited until conditions normalise. If a patient is considered suitable, the person will be invited to participate in the project. Participation in the trial is voluntary. Informed consent is obtained from the participants of the trial acc. Executive Order No. 1149 of 30 September 2013 on information and consent for participation in health science research projects and on notification and supervision of health science research projects. The first contact with the subject is made by admissions to one of the participating departments. Participant information is provided both orally and in writing, and the patient is informed that they are entitled to 24 hours of reflection time before consent is given for participation in the trial. Participants who wish to do so themselves after the period of deliberation may give consent in connection with the information meeting.

The oral information is provided by the project physician or by a doctor who has the prerequisites for communicating the content and who is directly related to the project. The right of occupant is ensured by the patient being able to bring a bystander, however, subject to COVID isolation rules. If no bystanders come to the first call, they are ensured afterwards to a bystander, when the patient is out of isolation. It is ensured that the conversations are undisturbed by using the patient's isolation room. If the doctor carries a "pager" or telephone, these are handed in prior to the call. The trial participant will be provided with the document "The research subject's rights in a health science research project", which contains information about confidentiality, access to documents and access to complaints. The subjects are protected under the Personal Data Processing Act. The trial has been reported to the Regional Science Ethics Committee, the Danish Medicines Agency and the Danish Data Protection Agency.

It must be ensured at all times that subjects have consented to participate in clinical trials. If an isolated subject with COVID-19 can sign consent declaration via electronic tool, this can be used instead of consent with signature. This can be, for example, a mobile phone, an iPad, a laptop with secure identification, for example by an easy ID (or other solution that meets the OCES standard). If the above described solution is not possible, the following solutions can be used as temporary documentation for the consent:

- Copy of signed consent declaration – e.g. using camera: The subject can sign the consent form as usual. Since the signed form must not leave the isolation room, the signature can be documented in the form of a photograph of the signed form, for example through a window.
- If the test subject cannot sign the consent declaration himself, e.g. due to problems with having electronic equipment in the room, or obtaining documentation for the consent out of the room, the witness can sign on behalf of the subject: If the subject verbally consents, a witness can on behalf of the subject sign the consent form. For both of the above solutions, documentation

## Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID)

(photo and witness signature) will be filed in the investigator's section of the Trial Master File (TMF). Furthermore, it is ensured that the Data Protection Regulation and the Data Protection Act are complied with, although documentation of the consent is temporarily different than it usually is. If the situation is normalised, the correct signed consent form must be obtained from the subject as soon as possible.

### **13. Exclusion and interruption of trials:**

Regular monitoring and quality control of the study will be carried out. If the physician responsible for the study deems it necessary, the physician may during treatment take the subject out of the study. The physician may also terminate the study at any time if there is a medical justification (such as the development of allergies to medicines), a safety risk or a requirement from the authorities. The test subject may also withdraw their informed consent and withdraw from the investigation at any time, as mentioned in the above paragraph.

### **14. Information on compensation and compensation schemes:**

Patients who participate in these studies and who believe they have suffered injury can seek compensation through the patient compensation (<http://patienterstatningen.dk/>) cf. Danish law.

### **15. References:**

1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020.
2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020.
3. Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. *Clin Infect Dis*. 2020.
4. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med*. 2020.
5. Murthy S, Gomersall CD, Fowler RA. Care for Critically Ill Patients With COVID-19. *JAMA*. 2020.
6. Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van't Veer NE, Ermens AA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. *Lancet Respir Med*. 2014;2(5):361-8.

Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalised Patients With COVID-19  
(ProPAC-COVID)

7. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Jr., Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. *N Engl J Med*. 2011;365(8):689-98.
8. Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2017;390(10095):659-68.
9. Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. *JAMA*. 2013;309(12):1251-9.
10. Segal LN, Clemente JC, Wu BG, Wikoff WR, Gao Z, Li Y, et al. Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung. *Thorax*. 2017;72(1):13-22.
11. Kawamura K, Ichikado K, Takaki M, Eguchi Y, Anan K, Suga M. Adjunctive therapy with azithromycin for moderate and severe acute respiratory distress syndrome: a retrospective, propensity score-matching analysis of prospectively collected data at a single center. *Int J Antimicrob Agents*. 2018;51(6):918-24.
12. Beigelman A, Mikols CL, Gunsten SP, Cannon CL, Brody SL, Walter MJ. Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis. *Respir Res*. 2010;11:90.
13. Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. *Eur Respir J*. 2010;36(3):646-54.
14. Li C, Zu S, Deng YQ, Li D, Parvatiyar K, Quanquin N, et al. Azithromycin Protects against Zika virus Infection by Upregulating virus-induced Type I and III Interferon Responses. *Antimicrob Agents Chemother*. 2019.
15. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? *Lancet Infect Dis*. 2003;3(11):722-7.
16. Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. *Nat Rev Nephrol*. 2011;7(12):718-29.
17. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. *Virology*. 2005;2:69.
18. Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. *Int J Antimicrob Agents*. 2020;55(3):105923.
19. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends*. 2020;14(1):72-3.